Previous Article | Next Article 
Journal of Bacteriology, June 2001, p. 3417-3427, Vol. 183, No. 11
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.11.3417-3427.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification and Functional Characterization of
Arylamine N-Acetyltransferases in Eubacteria: Evidence for
Highly Selective Acetylation of 5-Aminosalicylic Acid
Claudine
Deloménie,1
Sylvaine
Fouix,1
Sandrine
Longuemaux,1
Naïma
Brahimi,2
Chantal
Bizet,3
Bertrand
Picard,4
Erick
Denamur,1 and
Jean-Marie
Dupret1,*
INSERM U4581 and
Laboratoire d'Étude de Génétique
Bactérienne dans les Infections de l'Enfant
EA3105,2 Hôpital Robert Debré,
75019 Paris, Collection de l'Institut Pasteur, 75724 Paris
Cedex 15,3 and Laboratoire de
Microbiologie et de Santé Publique, Centre Hospitalier
Universitaire, 29609 Brest Cedex,4 France
Received 3 October 2000/Accepted 19 March 2001
 |
ABSTRACT |
Arylamine N-acetyltransferase activity has been
described in various bacterial species. Bacterial
N-acetyltransferases, including those from bacteria of the
gut flora, may be involved in the metabolism of xenobiotics, thereby
exerting physiopathological effects. We characterized these enzymes
further by steady-state kinetics, time-dependent inhibition, and DNA
hybridization in 40 species, mostly from the human intestinal
microflora. We report for the first time
N-acetyltransferase activity in 11 species of
Proteobacteriaceae from seven genera: Citrobacter
amalonaticus, Citrobacter farmeri, Citrobacter freundii, Klebsiella
ozaenae, Klebsiella oxytoca, Klebsiella rhinoscleromatis, Morganella
morganii, Serratia marcescens, Shigella flexneri, Plesiomonas
shigelloides, and Vibrio cholerae. We estimated
apparent kinetic parameters and found that 5-aminosalicylic acid, a
compound efficient in the treatment of inflammatory bowel diseases, was
acetylated with a catalytic efficiency 27 to 645 times higher than that
for its isomer, 4-aminosalicylic acid. In contrast,
para-aminobenzoic acid, a folate precursor in bacteria, was
poorly acetylated. Of the wild-type strains studied, Pseudomonas aeruginosa was the best acetylator in terms of both substrate spectrum and catalytic efficiency. DNA hybridization with a
Salmonella enterica serovar Typhimurium-derived probe
suggested the presence of this enzyme in eight proteobacterial and four
gram-positive species. Molecular aspects together with the kinetic data
suggest distinct functional features for this class of microbial enzymes.
 |
INTRODUCTION |
The acetyl coenzyme A
(AcCoA):arylamine N-acetyltransferases (NAT; EC 2.3.1.5.)
catalyze the transfer of an acetyl group from AcCoA to the nitrogen or
oxygen atom of primary arylamines, hydrazines, and their
N-hydroxylated metabolites. They therefore play important
roles in both the detoxification and metabolic activation of numerous
xenobiotics. In the Salmonella enterica serovar Typhimurium
mutation assays developed by Ames and coworkers (2), the
carcinogenic aromatic amines are N-hydroxylated and subsequently O-acetylated before they can exert genotoxic
properties. The O-acetylation step is mediated by the NAT of
S. enterica serovar Typhimurium, which therefore governs the
activity of many promutagens through N-hydroxyarylamine
O-acetyltransferase activity (26).
NAT isoforms (28) have been detected in several vertebrate
species, including human (6), rabbit (53),
rat (21), mouse (37), hamster
(23), and chicken (47). Partial data are also available for amphibian (30), helminth (12,
16), and insect (66) species. In prokaryotes, NATs
were first described in S. enterica serovar Typhimurium
(65) and then in several species of facultative and
obligate anaerobes of the dog and human intestinal microflora. NAT
activity has been reported in Escherichia coli, Bacteroides
vulgatus, Clostridium sporogenes, Lactobacillus bifidus, Proteus
vulgaris, Pseudomonas fluorescens, Enterococcus faecalis (48), Staphylococcus aureus (9),
Helicobacter pylori (18), Klebsiella
pneumoniae (32), Aeromonas hydrophila
(15), Enterobacter aerogenes (61),
Pseudomonas aeruginosa (33),
Lactobacillus acidophilus (11),
Citrobacter koseri (39), and Shigella
sonnei (62). However, NAT genes have been
cloned and their expression products characterized only for S. enterica serovar Typhimurium (57, 65),
Mycobacterium smegmatis, and Mycobacterium
tuberculosis (49).
The aminosalicylate isomers 5-aminosalicylic acid (5-ASA) and
4-aminosalicylic acid (4-ASA), both arylamine acceptor substrates of
human NATs, are used to treat inflammatory bowel diseases such as
ulcerative colitis and Crohn's disease (55, 59). 5-ASA is
considered one of the most efficient therapies for inducing and
maintaining remission in such diseases (50, 67). However, its use is associated with adverse side effects such as allergic rash,
pancreatitis, nephropathy, and hepatitis (41).
N-Acetylation activity for 5-ASA has been reported in both
aerobic and anaerobic intestinal microflora in human (63).
NATs from the bacteria of the intestinal microflora may therefore
affect both the efficacy and side effects of this drug.
The catalytic residues of NATs from eukaryotic and prokaryotic species
may be identical. Thus, the Cys69 residue in the NAT
sequence of S. enterica serovar Typhimurium has been shown
to be crucial for enzyme activity (65), and the homologous
Cys68 in humans probably plays a similar role
(22). The recent structure determination of S. enterica serovar Typhimurium NAT has revealed that the activation
of the active-site cysteine requires the presence of a
Cys69-His107-Asp122 catalytic triad
(58). In addition, it has been suggested that basic
residues highly conserved in all NAT sequences, at positions corresponding to Arg9 and Arg64 in the human
sequences, contribute to conformational stability and are involved in
the enzyme-substrate interactions of the human isoenzymes, NAT1 and
NAT2 (20). It has also been suggested that amino acids 125 and 127 are important determinants of NAT1-type and NAT2-type acceptor
substrate selectivity (24). Extending the study of
conserved residues to NATs from various bacterial species could
therefore provide new insight into the functional specificities of this
class of microbial enzymes.
As NATs in the bacteria of the gut microflora may be involved in the
activation of carcinogens and the metabolism of drugs, we used
functional and molecular approaches in an attempt to further identify
and characterize this class of enzymes. We experimentally studied
40 different bacterial species, most of which were indigenous to
the human gut. These species belonged to 30 genera from four different
taxonomic groups: gram-positive bacteria with high and low G+C
contents, Bacteroides, and Proteobacteria. The
Proteobacteria studied included the
Enterobacteriaceae, Vibrionaceae, and
Pasteurellaceae families. We characterized bacterial NATs
biochemically and compared them by determining their reaction spectra
with arylamine substrates known to be specific for the human NAT1 or
NAT2 isoform. We studied these enzymes kinetically using
aminosalicylate substrates. We also found some features that were
clearly common and specific to bacterial NATs, including a higher level
of activity for 5-ASA than for its isomer, 4-ASA.
 |
MATERIALS AND METHODS |
Chemicals.
5-ASA was purchased from Acros Organics. 4-ASA,
p-aminobenzoic acid (PABA), 2-aminofluorene (2-AF),
sulfamethazine (SMZ), procainamide (PA), iodoacetamide, AcCoA, and the
AcCoA-regenerating system D,L-acetylcarnitine
and carnitine acetyltransferase were all obtained from Sigma Chemical
Co. All other chemicals were of the highest purity commercially available.
Bacterial strains and growth conditions.
Two types of
strains were studied. First, six control strains were tested, including
the recombinant Escherichia coli strains DMG100 and DMG200
(22), which overproduce the human NAT1 and NAT2 isoforms,
respectively, and four S. enterica serovar Typhimurium tester strains originally constructed for genotoxicity quantitation assays. Of these strains, YG1024 (64) overexpresses
multiple copies of the NAT gene cloned from the TA1538 strain
(40), whereas the TA98 1,8/DNP6 strain
(43) produces no functionally active NAT. The TA98 strain
(40) differs from TA1538 only in its greater sensitivity
to mutagenesis. Second, the species listed in Table 1 were also studied. H. pylori
was cultured for 3 days on selective or sheep blood agar plates
(BioMérieux) in microaerobiosis conditions using an Oxoid Unipath
jar with a Campypack Plus microaerophilic generator (Becton Dickinson).
All other strains were cultured at 37°C until the exponential growth
phase, using a two-step procedure: 100 ml of medium was inoculated
using 10 ml of an 18-h culture and incubated for 3 h with shaking
(obligate and facultative aerobes) or for 72 h without shaking
(obligate anaerobes). Bacteria were grown in
Trypticase-yeast-glucose-cysteine or Rosenow broth
(Bacteroides sp.), from Sanofi Diagnostics Pasteur or in
Luria-Bertani medium from Difco Laboratories (all other strains). The
identity of the wild-type strains in each frozen glycerol stab was
routinely checked using API20E and/or ID32GN (for
Enterobacteriaceae, Aeromonas hydrophila, Plesiomonas
shigelloides, Vibrio cholerae, and P. aeruginosa),
API20NE (for Alcaligenes xylosoxidans), or Rapid ID32A (for
Bacteroides sp.) identification kits, with the ATB automated
expression system (BioMérieux). The purity of working cultures
obtained from these stabs was checked in each experiment by examining
the morphology of colonies from solid-medium cultures.
Enzyme assays.
Bacterial cells were harvested by
centrifugation (2,500 × g, 20 min, 4°C) and
resuspended in 2 ml of Tris (pH 7.4)-EDTA-dithiothreitol-KCl buffer
(22). The cells were lysed by sonication on ice twice for
30 s each, with a 30-s interval. The insoluble fraction was removed by centrifugation (20,000 × g, 5 min, 4°C),
and the resulting supernatant was used for NAT activity assays within
20 min of lysis. The soluble fraction of bacterial lysates contained 2 to 8 g of total proteins per liter, as assessed by a dye-binding assay (7). Lysates from DMG100 and DMG200 were prepared as previously described (22). NAT activity was also
determined in human feces collected from five unrelated healthy
Caucasian donors. Informed consent was obtained from all participants
in accordance with local ethical committee guidelines. Samples (1 to
2 g) of feces that had been stored at
80°C were suspended in
10 ml of Tris (pH 8.0)-EDTA-dithiothreitol-KCl buffer (22) supplemented with lysozyme (0.5 g/liter) and treated by sonication on
ice six times for 30 s each with 30-s intervals between pulses, to
facilitate lysis of gram-positive cells. The insoluble fraction was
sedimented by two centrifugation steps (2,500 × g, 5 min, 4°C, followed by 20,000 × g, 5 min, 4°C), and
the final supernatant was used in an assay of NAT activity.
Unless otherwise stated,
N-acetylation reactions were
performed at 37°C in the presence of 100 µM AcCoA and an
AcCoA-regenerating
system (
22). The NAT activity of
bacterial lysates was tested
in two or more 30-min reactions performed
in duplicate with 200
µM (for bacterial NATs) or lower
half-saturating concentrations
(for recombinant human NATs) of 2-AF,
5-ASA, 4-ASA, PABA, SMZ,
or PA as the arylamine acceptor substrate.
Arylamines and their
acetylated products were quantified by
reverse-phase high-pressure
liquid chromatography as previously
described (
20,
25). 5-ASA
and
N-acetyl-5-ASA
were eluted in a 7% (wt/wt) acetonitrile-20
mM sodium perchlorate (pH
2.5) mobile phase, with UV detection
at 264 nm, resulting in retention
times of 1.5 and 3.8 min, respectively.
The apparent
Km and
Vmax (± standard
error) values for 2-AF, 5-ASA,
4-ASA, PABA, and SMZ were determined
using a nonlinear fit analysis.
Steady-state kinetic parameters were
determined after checking
that rates of product formation were constant
throughout the reaction.
Kinetic studies were performed using arylamine
substrate concentrations
in the 0.1 to 10
Km
range unless substrate solubility was limitated,
as was the case for
2-AF. Maximum conversion rates of 10 to 20%
of the initial substrate
amount were obtained, if necessary by
diluting the cell lysate in
bovine serum albumin-containing buffer,
as reported (
20).
Inhibition studies.
To achieve irreversible inhibition by
iodoacetamide, undiluted cell extract was first incubated for 2 to 20 min at 25°C with various inhibitor concentrations. Aliquots were then
withdrawn, and residual NAT activity was measured in 5-min assays
performed at 25°C in the presence of 200 µM 2-AF without the
AcCoA-regenerating system. At the times indicated, the percent residual
activity was calculated by comparison with a control assay with the
same concentration of iodoacetamide but without prior incubation with inhibitor (set at 100%). For each inhibitor concentration, the logarithm of the percent residual activity was plotted against the
length of time for which the cell extract was incubated with inhibitor.
Hybridization analysis.
Southern blotting was carried out on
genomic DNA from 22 of the wild-type Proteobacteria species
studied. Genomic DNA was digested with EcoRI, size
fractionated by electrophoresis in a 1% agarose gel, and transferred
to a nylon membrane by capillary blotting. Genomic DNA from
Proteobacteria and gram-positive strains was amplified by
PCR using the BACT5 and BACT3 degenerate primers in the following
thermocycling procedure: 5 min of denaturation at 94°C, 2 min of
hybridization at 46 or 50°C, and then 40 cycles including 1 min of
denaturation at 94°C, 30 s of hybridization at 46 or 50°C, and
2 min of extension at
72°C.
BACT5: 5'-CATGCTTACTTCACGAGA-3' T T C C
G
T
BACT3: 5'-CGCGGCCAGCTCCGCCTC-3' A T
G
T
The MgCl
2 concentration of the PCR mixture
was 4 mM for hybridization at 46°C and 3 mM for hybridization at
50°C. To test
for the presence of
NAT-hybridizing
sequences in genomic and PCR-amplified
bacterial DNA, a 184-bp probe
including the region encoding the
active site of the
S. enterica serovar Typhimurium NAT (positions
124 to 307 from the
initiation codon, GenBank accession number
D90301) was generated by
PCR. Primers SALM5 (5'-GATGTGCTACTGCCTCGTGAA-3')
and SALM3 (5'-GTAAACTGGCGGGATGAGACA-3') were
used in the presence
of 1.5 mM MgCl
2 with the
thermocycling procedure described above
except that hybridization was
performed at 60°C. The amplified
DNA was labeled with
[

-
32P]dCTP using a random priming kit (Roche
Diagnostics) and used
in standard conditions to probe genomic or
PCR-amplified
DNA.
 |
RESULTS |
Comparison of substrate selectivity of bacterial NATs.
2-AF,
which is efficiently acetylated by both human NAT1 and NAT2, was used
for comparative screening of NAT activity levels in gram-negative
species found in the human gut microflora, including 23 Proteobacteria and one Bacteroides species. The
TA98, TA1538, and YG1024 (NAT-overproducing) S. enterica
serovar Typhimurium strains were used as positive controls. Enzyme
activity was also tested using the structurally related human
NAT1-selective PABA, 4-ASA, and 5-ASA (Fig.
1) and the human NAT2-selective SMZ and PA arylamine substrates (Table 2). The
E. coli control strains DMG100 and DMG200, which overproduce
the recombinant human NAT1 and NAT2 isoenzymes, respectively, displayed
the expected level of activity with the substrates tested.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of chemical structures of PABA, 4-ASA, and
5-ASA. 4-ASA is also called p-aminosalicylic acid in the
literature.
|
|
Significant NAT activity was identified for the first time in 11
Proteobacteria species from seven different genera:
C. amalonaticus, C. farmeri, C. freundii, K. ozaenae, K. oxytoca, K. rhinoscleromatis, M. morganii, S. marcescens, S. flexneri, P. shigelloides, and
V. cholerae. Fifteen
Proteobacteria species had detectable NAT
activity with
2-AF. With the exception of
M. morganii, H. pylori,
and
E. coli K-12, the species or genera that acetylated 2-AF
also
acetylated 5-ASA, whereas the
Bacteroides sp.
acetylated 5-ASA
but not 2-AF. Of the arylamines tested, 5-ASA and, to
a lesser
extent, 2-AF were the most highly acetylated by bacteria in
our
experimental conditions, with velocities of 0.006 (
S. marcescens)
to 2.20 (
P. aeruginosa) and of 0.002 (
M. morganii) to 1.06 (
P. aeruginosa) nmol
min
1 (mg of protein)
1, respectively.
P. aeruginosa, E. coli 54.8,
C. freundii, C. koseri,
and
C. farmeri, which acetylated both
aminosalicylate isomers
studied, had 8, 22, 50, 65, and 65 times higher levels of activity,
respectively, with 5-ASA than with
4-ASA.
Only 4 of the 22 species tested for
N-acetylation of PABA
exhibited significant activity, from 0.002 (
A. hydrophila)
to 0.14
(
P. aeruginosa) nmol min
1 (mg of
protein)
1.
P. aeruginosa, C. amalonaticus, and
S. enterica serovar Typhimurium
YG1024 acetylated 5-ASA 11, 21, and 1,480 times more efficiently
than PABA, respectively, whereas
N-acetylation velocities were
of the same order of magnitude
for both compounds in the
Bacteroides sp. With the exception
of
P. aeruginosa, which showed similar
levels of activity
with PABA and 4-ASA, the PABA-acetylating species
did not acetylate
4-ASA.
The bacterial species studied displayed a low level of
N-acetylation activity with SMZ and PA in our experimental
conditions
(from 0.001 to 0.006 nmol min
1 [mg of
protein]
1). PA was acetylated only by
C. amalonaticus, and
P. shigelloides, P. vulgaris, P. alcalifaciens, and
A. xylosoxidans had no detectable
NAT activity with the arylamine substrates studied here, nor did
the
NAT-defective
S. enterica serovar Typhimurium TA98/1,8
DNP
6 strain used as a negative control. Overall,
P. aeruginosa appeared
from our comparative screening to be the most
potent
N-acetylator
among the species studied, as it
acetylated 2-AF and the three
human NAT1-specific substrates with the
highest velocity
values.
NAT activity in human colonic content.
We estimated the
overall N-acetylation activity of the colonic microflora by
performing enzyme assays with lysates of human feces and 5-ASA or 2-AF
as the acceptor substrate. Samples collected from the various donors
displayed NAT activity with 5-ASA (0.062 ± 0.011, 0.063 ± 0.014, 0.079 ± 0.007, 0.113 ± 0.021, and 0.639 ± 0.049 nmol min
1 per g of initial sample). Conversely, the
N-acetylation velocities by fecal lysates of 2-AF were lower
than 0.015 nmol min
1 per g in our experimental
conditions. Given the estimated bacterial content in feces
(4) and in our bacterial cultures (optical density at 600 nm), it can be roughly estimated that the feces lysates were made from
10 to 100 times less bacteria than the pure-culture lysates.
Comparative kinetics of bacterial NATs.
The strains found to
have the highest rates of enzyme activity in the reaction spectrum
study were studied in more detail to characterize further and compare
their N-acetylation activities. We determined apparent
kinetic parameters for these strains (Tables 3 to 5). The five arylamine acceptor
substrates studied can be assigned to three overlapping classes on the
basis of their apparent Km: (i) 5-ASA (26 to 350 µM), 2-AF (44 to 405 µM), and SMZ (59 to 550 µM); (ii) 4-ASA (260 to 2,200 µM); and (iii) PABA (870 to 51,600 µM). Bacterial NATs had
similar apparent affinities for 5-ASA, 2-AF, and SMZ, as shown by the
weak differences between the corresponding Km
values for a given strain. Conversely, bacterial N-acetylation of the aminosalicylate isomers studied
displayed a higher affinity for 5-ASA. The Km of
4-ASA was 4 times higher than that of 5-ASA in C. koseri, 10 times higher in P. aeruginosa, 11 times higher in E. coli 54.8, 14 times higher in C. freundii, and 29 times
higher in C. farmeri. Similarly, the
Km of human NAT2 for 4-ASA was 41 times higher
than that for 5-ASA, whereas human NAT1 acetylated both isomers with
similar Michaelis constants. The Km values of
bacterial NATs and human NAT2 were of the same order of magnitude for
5-ASA. Finally, of the arylamines studied, PABA was the substrate for
which bacterial NATs had the lowest apparent affinity, as indicated in
P. aeruginosa by Km values 5, 27, and
47 times higher than those for 4-ASA, 2-AF, and 5-ASA, respectively.
In any given strain, the apparent
Vmax for 5-ASA
acetylation by the bacterial NAT was higher than that for any other
substrate
(Table
4). Similarly, the
highest catalytic efficiencies,
Vmax/
Km,
were also
measured for 5-ASA in bacteria (Table
5).
In particular,
Vmax/
Km
values were 27 (for
E. coli 54.8) to 645 (for
C. farmeri)
times higher for 5-ASA than for 4-ASA, consistent with
the
Km data. Human recombinant NAT2 also had a
Vmax/
Km for 5-ASA that
was 32 times higher than that for 4-ASA, whereas NAT1 had similar
catalytic efficiencies with both isomers. Human recombinant NAT1
acetylated PABA with the highest
Vmax/
Km (
22)
(Table
5), whereas
in
P. aeruginosa, the catalytic
efficiency of PABA acetylation
was 1/100 that for 5-ASA and 1/30 that
for 2-AF. In
S. enterica serovar Typhimurium YG1024, the
catalytic efficiency was 1,500
times higher for 2-AF than for PABA.
Conversely,
P. aeruginosa displayed similar
Vmax/
Km values for PABA
and 4-ASA. Finally,
the catalytic efficiencies for the acetylation of
SMZ by bacterial
NATs were of the same order of magnitude or lower than
those for
4-ASA in a given species.
Consistent with the results obtained for the reaction spectra of
bacterial NATs, with the exception of the recombinant NAT-overproducing
strains,
P. aeruginosa was the most efficient acetylator
among
the species studied for each arylamine substrate tested. It
exhibited
Vmax/
Km values
64, 25, and 8 times higher than those of
S. enterica serovar
Typhimurium for 2-AF, 5-ASA, and PABA, respectively. Its
Vmax/
Km for 4-ASA was
also 43 times higher than that of
E. coli 54.8. In contrast
S. marcescens, H. pylori, and
M. morganii
displayed
the lowest catalytic efficiencies for 2-AF in our
experimental
conditions.
Inhibition of bacterial NAT activity.
To obtain further
insight into the nature of the putative active amino acid residue of
bacterial NATs, we performed irreversible inhibition experiments with
iodoacetamide. This compound irreversibly reacts with the thiol group
of accessible Cys side chains in proteins to give a stable alkylated
product (19). Bacterial lysates from S. enterica serovar Typhimurium YG1024, C. koseri, and
P. aeruginosa were incubated with or without 100 to 800 mM
iodoacetamide, corresponding to a 200 to 1,600-fold molar excess of the
modifying agent over the estimated Cys residue content of bacterial
lysates (45), and the residual NAT activity was measured
in the presence of 2-AF. The inactivation of NAT depended on time and
inhibitor concentration (Fig. 2).
Apparent pseudo-first-order inactivation constants
(Kobs) were obtained for each iodoacetamide
concentration by linear regression of plots of the logarithm of the
percentage of control activity versus time (38). Secondary
plots of ln (Kobs) versus ln (iodoacetamide) were linear and had slopes of 0.81 for S. enterica serovar
Typhimurium YG1024, 0.72 for C. koseri, and 1.07 for
P. aeruginosa. Thus, the order of the inhibition reaction
with iodoacetamide was probably similar for these three bacterial NAT
activities. In each case, we estimated that a single functional Cys
reacted with the modifying agent.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 2.
Time- and concentration-dependent inactivation of
bacterial NATs with iodoacetamide. Cell extracts from S. enterica serovar Typhimurium YG1024 (A), C. koseri (B),
and P. aeruginosa (C) were incubated without ( ) or with
iodoacetamide at a final concentration of 100 ( ), 200 (×), 400 ( ), 600 ( ), or 800 ( ) mM, and residual
N-acetylation activity with 2-AF was measured. Results are
the means of two experiments performed in duplicate. Insets show the
double-logarithmic plots of the apparent first-order inactivation rate
(kobs) versus molar inhibitor concentration. A
value of 0.81 (r = 0.99), 0.72 (r = 0.99) and 1.07 (r = 0.98) for the reaction order
(n) with respect to iodoacetamide was calculated from the
slopes for S. enterica serovar Typhimurium YG1024, C. koseri, and P. aeruginosa, respectively. The initial
reaction rates without inhibitor were 11.23 ± 0.63, 0.42 ± 0.02, and 2.93 ± 0.03 nmol min 1 (mg of
protein) 1 for S. enterica serovar Typhimurium
YG1024, C. koseri, and P. aeruginosa,
respectively.
|
|
Molecular hybridization of DNA from several bacterial species with
an S. enterica serovar Typhimurium NAT probe.
Having
detected NAT activity in a number of bacterial species, we attempted to
detect new NAT-encoding regions. Genomic DNA from various bacterial
species was amplified by PCR at two different levels of stringency,
using degenerate primers derived from the sequence of the S. enterica serovar Typhimurium NAT gene. The degenerate sense
(BACT5) and antisense (BACT3) primers used hybridized to the coding
sequence of the S. enterica serovar Typhimurium NAT gene at
positions 16 to 33 and 797 to 804, respectively, resulting in a PCR
product of 788 bp for S. enterica serovar Typhimurium. We
checked the specificity of the amplified DNAs by Southern blotting of
the PCR products, using a radiolabeled 184-bp DNA probe amplified by
PCR from the putative active-site region of the S. enterica serovar Typhimurium NAT gene (i.e., spanning the Cys69
residue) (Fig. 3). All positive strains
gave the expected band of approximately 790 bp. An unidentified 500-bp
band was also detected. In addition to S. enterica serovar
Typhimurium, 8 of the 22 proteobacteria (5 members of the
Enterobacteriaceae [C. koseri, C. freundii, E. coli 54.8, K. ozaenae, and S. marcescens] and 3 species from other families [B. bronchiseptica, P. multocida, and P. aeruginosa]) as well as 4 of the 12 gram-positive species studied (2 with a high G+C content
[Corynebacterium urealyticum and C. xerosis]
and 2 with a low G+C content [S. aureus and S. mitis]) produced a signal. A faint signal was obtained for
Streptococcus A and S. pneumoniae. Genomic DNA
blots (EcoRI digests) from all Proteobacteria
strains studied except E. coli K-12 and H. pylori (Table 1) were also incubated with the probe (data not shown). The
presence or absence of hybridization signals was recorded with
PCR-amplified as well as genomic DNA blots (Fig. 3). Of all the species
studied only by genomic DNA hybridization, only K. pneumoniae and S. flexneri provided a faint
hybridization signal.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
Hybridization of PCR-amplified bacterial DNA with the
S. enterica serovar Typhimurium NAT probe PCR products
amplified from bacterial genomic DNA were blotted as described in the
text. A negative control consisting of an 835-bp amplification product
of the human NAT2 coding region was blotted in the control lane. The
hybridization temperature and MgCl2 content used for PCR
were 50°C and 3 mM (left blot) or 46°C and 4 mM (central and right
blots). Similar hybridization results were obtained for both sets of
PCR conditions for the S. enterica serovar Typhimurium DNA
blot. In addition to the expected 790-bp band (left arrow), an
unidentified 500-bp band was also detected. A similar doublet was found
for S. enterica serovar Typhimurium at shorter exposure
time. Some of the strains (group A) also gave a positive signal by
hybridization of EcoRI-digested genomic DNA. The right arrow
indicates the direction of electrophoretic migration.
|
|
 |
DISCUSSION |
In this study, we used molecular and functional approaches to
identify and characterize bacterial NATs. Thirteen NAT sequences from
nine eubacterial genera were retrieved from databases, using the
S. enterica serovar Typhimurium NAT sequence as a query, and were multialigned (data not shown). These sequences showed a highly conserved Cys that aligned with Cys69 in S. enterica serovar Typhimurium (65), which has been
suggested to be the active-site residue in four bacterial NATs
(49). We inhibited the NAT activity from P. aeruginosa, C. koseri, and S. enterica serovar
Typhimurium YG1024 by a large excess of the Cys-modifying agent
iodoacetamide. We found that this inhibition followed a 1:1
stoichiometry, suggesting that one essential Cys residue is accessible
to the inhibitor in these three bacterial enzymes (Fig. 2). The
essential nature of Cys69 in S. enterica serovar
Typhimurium has already been demonstrated by Watanabe and colleagues
(65) from site-directed mutagenesis experiments. Thus,
like vertebrate NATs (20), eubacterial isoforms seem to
have a single Cys as the active-site residue. Our sequence alignment
(data not shown) identified two strictly conserved residues aligning
with His107 and Asp122 of the S. enterica serovar Typhimurium NAT. These residues have recently
been described as forming part of its catalytic triad (58). We also identified two highly conserved basic
residues aligning with Arg9 and Arg64 of human
NATs. It has been suggested that the Arg9 and
Arg64 residues are essential for enzyme-substrate
interactions and conformational stabilization in vertebrate NATs
(20). The conservation of these residues
(Arg11 and Arg65 of S. enterica
serovar Typhimurium NAT) suggests that similar mechanisms may operate
for all NATs. The structural study of S. enterica serovar
Typhimurium NAT conducted by Sinclair et al. (58) supports
that hypothesis. In particular, it was found that Arg65
stabilizes the conformation of the Cys69 residue through a
salt bridge interaction with the highly conserved Glu39.
We identified NAT activity for the first time in 11 proteobacterial
species belonging to the Citrobacter, Klebsiella, Morganella, Serratia, Shigella, Plesiomonas, and Vibrio genera
(Table 2). These enzyme activities were detected and some of them were
kinetically characterized using one or several of six arylamine
acceptor substrates chosen as NAT1-type (PABA, 4-ASA, and 5-ASA),
NAT2-type (SMZ and PA), or mixed (2-AF) with regard to substrate
selectivity of human NATs. The values obtained for the S. enterica serovar Typhimurium control strains showed that these
activities were specific (Tables 3 to 5). It has to be noted that our
Km values for 2-AF in P. aeruginosa, E. coli, and H. pylori lysates are 3 to 35 times lower than those reported by Chung et al. (8, 10, 33). These discrepancies may be related to differences in experimental conditions, such as AcCoA concentration and waiting time between bacterial sonication and NAT assay. We observed that above a 20-min interval between cell lysis and enzymatic assay, the apparent
Km values could markedly increase, with loss in
reproducibility. This might contribute to the variability in kinetic
parameter values reported in distinct studies by Chung et al.
(10, 13, 14, 17).
Bacterial NAT activities appear to have features similar to those of
the human NAT1 and NAT2 isoenzymes. They are most similar to NAT1 in
terms of reaction spectrum, as shown by their low
N-acetylation activity with the NAT2-selective substrates
SMZ and PA (Table 2) and by their high catalytic efficiency with 5-ASA
and 2-AF compared to that with SMZ (Tables 3 to 5). This may be
related, in 11 of the 13 bacterial sequences retrieved, to the presence of a conserved Phe residue aligning with Phe125 in the
human NAT1 sequence (data not shown). This residue may be associated
with the low NAT1-type substrate selectivity for SMZ (24).
In contrast, most of the bacterial NATs studied had poor or
undetectable activity with PABA, which makes them similar to human NAT2
(Table 2). The ranges of apparent Km values for SMZ, 5-ASA, and 4-ASA also place bacterial NATs closer to human NAT2
than to NAT1. Consistently, the NAT from M. smegmatis
exhibits a low apparent Km (25 µM) for the
NAT2 substrate isoniazid (49). We found that bacterial
NATs share with human NAT2 a higher catalytic efficiency for 5-ASA than
for its isomer, 4-ASA (Tables 3 to 5). The bacterial sequences studied
have no conserved residue aligning with Arg127 in the human
NAT1 sequence (data not shown). This residue may be associated with the
high selectivity of human NAT1 for 4-ASA (24). Finally,
bacterial NATs appear to have functional specificities that distinguish
them from their eukaryotic counterparts, making them useful as a new
model for study of the structure-function relationships of arylamine
N-acetyltransferases.
Enterobacteriaceae species (Table 1) widely acetylated one
or more of the tested arylamines. Most of them cross-reacted with the
previously described rabbit antiserum raised against purified recombinant S. enterica serovar Typhimurium NAT
(49) and gave an immunoblot signal comigrating with the
S. enterica serovar Typhimurium NAT band (data not shown),
consistent with other data (M. Payton, A. Mushtaq, J. Sinclair, J. Sandy, T.-W. Yu, M. Noble, and E. Sim, submitted for publication).
However, unlike a previous study (48), we did not detect
NAT activity in P. vulgaris, possibly due to differences in
the strains used. The E. coli 54.8 and K-12 strains
consistently differed in NAT activity in this study. This may be due to
the high polymorphism within the E. coli species reflected
by differences in genome length (5) or in metabolic phenotypes (36) between strains. P. alcalifaciens and A. xylosoxidans also had no
detectable activity for the six arylamine substrates tested in our
study. The low nutritive content of our bacterial growth medium is
unlikely to play a significant role in this lack of enzyme activity
because these species are members of the normal intestine microflora
and the contents of the colonic lumen are considered nutritively poor.
Although these three inactive species gave no signal in genomic DNA
hybridization experiments, they gave a clear NAT-specific
immunoreactivity signal (data not shown). This suggests that these
organisms may contain NATs with a different and unknown substrate
selectivity. The Pasteurellaceae species P. multocida did not acetylate 2-AF in our test conditions, but the
positive results of DNA hybridization experiments (Fig. 3) suggest that
this species contains a genomic sequence with some similarities to the
S. enterica serovar Typhimurium NAT gene.
The four Vibrionaceae species studied were only weakly
immunoreactive with the S. enterica serovar
Typhimurium-specific antiserum (data not shown) and had marginal NAT
activities. H. pylori acetylated 2-AF much less efficiently
than in previous studies (10, 18) (Table 2). We were also
unable to retrieve a putative NAT sequence from the H. pylori genome database even though two unrelated strains have been
now completely sequenced (1, 60). Only a partial putative
sequence was obtained from the V. cholerae genome (data not
shown). Consistently, no genomic DNA hybridization signal was obtained
for V. cholerae, A. hydrophila, and P. shigelloides (data not shown). This suggests that the NATs of the
Vibrionaceae differ greatly in structure and reaction
spectrum from those found in other proteobacteria. In contrast, within
obligate anaerobes, we found significant NAT activity for PABA and
5-ASA in the Bacteroides sp. (Table 2) and a small activity
with 2-AF and 5-ASA in C. difficile (data not shown),
consistent with previous data for these genera (48).
However, the absence of a detectable immunoblot signal for the
Bacteroides sp. (data not shown) may be related to the
absence of an epitope in common with S. enterica serovar Typhimurium NAT.
Among the Proteobacteria and Bacteroides species
tested here, P. aeruginosa was the most effective
N-acetylator in terms of both reaction spectrum and
catalytic efficiency, since it exhibited the highest activity for 2-AF,
5-ASA, 4-ASA, and PABA (Tables 2, 3, 4, and 5). P. aeruginosa gave NAT-specific DNA hybridization (Fig. 3) and
cross-immunoreactivity (data not shown) signals. A complete putative
NAT sequence was also obtained from this species (data not shown).
Moreover, the results of our DNA hybridization experiments (Fig. 3) and
the identification of several putative NAT sequences (data not shown)
suggest that NATs are widely present in gram-positive species with low
and high G+C contents.
Microbial interactions and drug administration are determinants for the
composition of the intestinal microflora. Therefore, the identification
of bacterial NATs may serve as a means of understanding the enzyme
activity in different clinical situations. The aminosalicylate 5-ASA is
one of the most effective treatments for inflammatory bowel diseases in
humans (50). It is mainly metabolized into N-acetyl-5-ASA, which is thought to be therapeutically
inactive (35). We detected N-acetylation
activity with 5-ASA in human feces, with a 1- to 10-fold
interindividual variability in enzyme velocities (see Results). This
activity mostly reflects that of obligate anaerobes, including
gram-positives, as they constitute the great majority of the colonic
microflora (4, 56). These results are consistent with the
ability of the Bacteroides sp. (Table 2) and of the entire
obligate anaerobic colonic microflora in culture (63) to
N-acetylate 5-ASA. The absence of a detectable NAT activity
for 2-AF in feces samples is also consistent with the lack of activity
found with the Bacteroides sp. (Table 2). The endogenous
NAT1 activity of intestinal mucosal cells (29) is unlikely
to contribute to the observed N-acetylation of 5-ASA in
feces, given that (i) maximal N-acetyl-5-ASA synthesis was reported for high dilutions of fecal material in humans
(63) and (ii) the endogenous pancreatic enzymes present in
the intestinal content are greatly inactivated by the microflora in
rats (51). We detected NAT activity with 5-ASA in species
of Proteobacteria and Bacteroides from the
intestinal microflora, including members known to be overrepresented in
inflammatory bowel diseases. These microbes include the aerobes
E. coli, P. aeruginosa, and Klebsiella (31) and the obligate anaerobes Bacteroides
(3, 46) and C. difficile (52). Of
the various arylamines tested here, 5-ASA was the most efficiently
acetylated by bacterial NATs (Tables 2, 3, 4, and 5). Bacterial
N-acetylation may therefore be responsible, in addition to
the intestinal metabolism (68), for 5-ASA inactivation.
However, N-acetyl-5-ASA has itself been found to inhibit the
growth of obligate anaerobes such as C. difficile (52). We also found that NATs from P. aeruginosa, E. coli, and various Citrobacter species had stronger
activity for 5-ASA than for its isomer, 4-ASA (Tables 3, 4, and 5).
Similar therapeutic benefits have been reported for both isomers in
specific cases of ulcerative colitis, and patient tolerance of 4-ASA is
higher due to the adverse effects of 5-ASA (42). The use
of 4-ASA in inflammatory bowel disease patients presenting intolerance
to 5-ASA may therefore be recommended, given its low level of
inactivation by intestinal microflora. N-Acetyl-5-ASA may be
unstable in the intestine and/or hydrolyzed by nonspecific amidases to
regenerate 5-ASA. However, administered acetyl-5-ASA was reported not
to be deacetylated, and acetyl-5-ASA is considered more stable than 5-ASA (35). Thus, we suggest that the bacterial
acetylation of 5-ASA could modulate the concentration equilibrium
between the two forms, promoting the acetylated form in the gut. Other works have highlighted the importance of the metabolism of intestinal bacteria in drug side effects (44). Consistently, NAT
activity in Mycobacterium species was suggested to modulate
the therapeutic response to isoniazid treatment of tuberculosis.
It should be important to investigate such prokaryotic NATs for
polymorphism and potential implications for drug resistance
(54).
In contrast to previous reports (8, 18), only a small
proportion of the bacterial species studied here acetylated PABA (Table
2). In addition, it was previously observed that bacterial NATs have
lower activities with PABA than with 2-AF (33, 48), although with similar apparent Km (8, 10,
18). In our study, reactions with PABA had much lower catalytic
efficiencies than those with 2-AF or with the structurally related
5-ASA, mainly due to the higher apparent Km
values measured for PABA (Table 3). The results of reversible
inhibition experiments suggested that PABA acts as a competitive
inhibitor for the N-acetylation of 2-AF in S. enterica serovar Typhimurium 60.62 (data not shown). These data
are consistent with the essential role of PABA as a precursor for
folate synthesis in bacteria and suggest a double level of preservation
of the PABA pool in the bacterial cell with regard to
N-acetylation (34, 49).
Bacterial NATs have been shown to have the potential to generate
strongly alkylating cationic compounds involved in carcinogenesis, through N- and/or O-acetylation of arylamine or
hydroxyarylamine metabolites (27). Microflora and
endogenous NATs may thus affect susceptibility to human bowel cancers,
in addition to other bacterial carcinogen-producing pathways such as
nitroreduction and azoreduction (56). The data presented
here may ultimately make it possible to design new tester strains with
higher efficiencies in mutagenicity tests. To this end, we suggest that
the P. aeruginosa NAT should be further investigated at the
molecular level. Indeed, this study shows that this enzyme is
potentially useful in terms of both the substrate diversity and the
activity levels required in such tests. However, further kinetic
studies on purified enzyme are necessary, since differences in enzyme
activities can be due to differences in catalytic properties but also
to differences in expression levels.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the Ligue Nationale contre
le Cancer (France).
We thank Philippe Quillardet (Laboratoire de Programmation
Moléculaire et Toxicologie Génétique, Institut
Pasteur, Paris, France) for kindly providing the S. enterica
serovar Typhimurium Ames tester strains. We are grateful to Edith Sim
(Department of Pharmacology, Oxford University, Oxford, England) for
the kind gift of rabbit antiserum raised against purified recombinant
S. enterica serovar Typhimurium NAT and for sharing
preliminary data. We also thank Jacques Elion for constant
encouragement during this work and Rajagopal Krishnamoorthy, Philippe
Marteau, Mark Payton, and Sylvie Rabot for helpful discussion. We also
thank Catherine Arnaudeau for technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Present address: CNRS UMR 7000, Faculté de Médecine Pitié-Salpêtrière,
105 boulevard de l'Hôpital, 75013 Paris, France. Phone: (33 1)
53 60 08 03. Fax: (33 1) 53 60 08 02. E-mail:
jmdupret{at}infobiogen.fr.
 |
REFERENCES |
| 1.
|
Alm, R. A.,
L. S. Ling,
D. T. Moir,
B. L. King,
E. D. Brown,
P. C. Doig,
D. R. Smith,
B. Noonan,
B. C. Guild,
B. L. deJonge,
G. Carmel,
P. J. Tummino,
A. Caruso,
M. Uria-Nickelsen,
D. M. Mills,
C. Ives,
R. Gibson,
D. Merberg,
S. D. Mills,
Q. Jiang,
D. E. Taylor,
G. F. Vovis, and T. J. Trust.
1999.
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.
Nature
397:176-180[CrossRef][Medline]. (Erratum, 397:719.)
|
| 2.
|
Ames, B., and L. S. Gold.
1997.
Environmental pollution, pesticides, and the prevention of cancer: misconceptions
FASEB J.
11:1041-1052[Abstract].
|
| 3.
|
Bamba, T.,
H. Matsuda,
M. Endo, and Y. Fujiyama.
1995.
The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis.
J. Gastroenterol.
30:45-47.
|
| 4.
|
Berg, R. D.
1996.
The indigenous gastrointestinal microflora.
Trends Microbiol.
4:430-435[CrossRef][Medline].
|
| 5.
|
Bergthorsson, U., and H. Ochman.
1998.
Distribution of chromosome length variation in natural isolates of Escherichia coli.
Mol. Biol. Evol.
15:6-16[Abstract].
|
| 6.
|
Blum, M.,
D. M. Grant,
O. M. McBride,
M. Heim, and U. A. Meyer.
1990.
Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression DNA.
Cell. Biol.
9:193-203.
|
| 7.
|
Bradford, M. M.
1976.
A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[CrossRef][Medline].
|
| 8.
|
Chang, F. C., and J. G. Chung.
1998.
Evidence for arylamine N-acetyltransferase activity in the Escherichia coli.
Curr. Microbiol.
36:125-130[CrossRef][Medline].
|
| 9.
|
Chang, F. C.,
J. G. Chung,
W. C. Chang,
L. T. Wu,
G. W. Chen, and S. H. Chang.
1997.
Arylamine N-acetyltransferase activity in Staphylococcus aureus.
J. Microbiol. Immunol. Infect.
30:170-181[Medline].
|
| 10.
|
Chang, S. H.,
J. G. Chung,
L. J. Huang,
S. C. Chen, and S. C. Kuo.
1998.
Ibuprofen affects arylamine N-acetyltransferase activity in Helicobacter pylori from peptic ulcer patients.
J. Appl. Toxicol.
18:179-185[CrossRef][Medline].
|
| 11.
|
Chen, G. W.,
C. F. Hung,
S. H. Chang,
J. G. Lin, and J. G. Chung.
1999.
Purification and characterization of an arylamine N-acetyltransferase from Lactobacillus acidophilus.
Microbios
98:159-174[Medline].
|
| 12.
|
Chung, J. G.,
H. Kuo,
T. Lin,
C. Ho,
J. Lee,
J. Lai,
G. Levy, and W. Weber.
1996.
Evidence for arylamine N-acetyltransferase in the nematode Anisakis simplex.
Cancer Lett.
106:1-8[CrossRef][Medline].
|
| 13.
|
Chung, J. G.
1999.
The effects of vitamin E on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients.
Food Chem. Toxicol.
37:655-661[CrossRef][Medline].
|
| 14.
|
Chung, J. G.
1998.
Inhibitory actions of ellagic acid on growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients.
Microbios
93:115-127[Medline].
|
| 15.
|
Chung, J. G.
1998.
Purification and characterization of an arylamine N-acetyltransferase from the bacteria Aeromonas hydrophilia.
Curr. Microbiol.
37:70-73[CrossRef][Medline].
|
| 16.
|
Chung, J. G.,
H. M. Kuo,
L. T. Wu,
J. M. Lai,
J. H. Lee, and C. F. Hung.
1997.
Evidence for arylamine N-acetyltransferase in Hymenolepis nana.
J. Microbiol. Immunol. Infect.
30:1-17[Medline].
|
| 17.
|
Chung, J. G.,
M. F. Tsou,
H. H. Wang,
H. H. Lo,
S. E. Hsieh,
Y. S. Yen,
L. T. Wu,
S. H. Chang,
C. C. Ho, and C. F. Hung.
1998.
Rhein affects arylamine N-acetyltransferase activity in Helicobacter pylori from peptic ulcer patients.
J. Appl. Toxicol.
18:117-123[CrossRef][Medline].
|
| 18.
|
Chung, J. G.,
H. H. Wang,
M. F. Tsou,
S. E. Hsieh,
H. H. Lo,
Y. S. Yen,
S. S. Chang,
L. T. Wu,
J. H. Lee, and C. F. Hung.
1997.
Evidence for arylamine N-acetyltransferase activity in the bacterium Helicobacter pylori.
Toxicol. Lett.
91:63-71[CrossRef][Medline].
|
| 19.
|
Creighton, T. E.
1993.
Amino acid residues, p. 6-20.
In
Proteins: structures and molecular properties, 2nd ed. W. H. Freeman and Co., New York, N.Y.
|
| 20.
|
Deloménie, C.,
G. H. Goodfellow,
R. Krishnamoorthy,
D. M. Grant, and J.-M. Dupret.
1997.
Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis.
Biochem. J.
323:207-215.
|
| 21.
|
Doll, M. A., and D. W. Hein.
1995.
Cloning, sequencing and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats.
Pharmacogenetics
5:247-251[Medline].
|
| 22.
|
Dupret, J.-M., and D. M. Grant.
1992.
Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli.
J. Biol. Chem.
267:7381-7385[Abstract/Free Full Text].
|
| 23.
|
Ferguson, R.,
M. Doll,
T. Rustan, and D. Hein.
1996.
Cloning, expression and functional characterization of rapid and slow acetylator polymorphic N-acetyltransferase encoding genes of the syrian hamster.
Pharmacogenetics
6:55-66[CrossRef][Medline].
|
| 24.
|
Goodfellow, G. H.,
J.-M. Dupret, and D. M. Grant.
2000.
Identification of amino acids imparting acceptor substrate selectivity in human arylamine acetyltransferases NAT1 and NAT2.
Biochem. J.
348:159-166.
|
| 25.
|
Grant, D. M.,
M. Blum,
M. Beer, and U. A. Meyer.
1991.
Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Mol. Pharmacol.
39:184-191[Abstract].
|
| 26.
|
Grant, D. M.,
P. D. Josephy,
H. L. Lord, and L. D. Morrison.
1992.
Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines.
Cancer Res.
52:3961-3964[Abstract/Free Full Text].
|
| 27.
|
Hein, D. W.,
M. A. Doll,
T. D. Rustan,
K. Gray,
Y. Feng,
R. J. Ferguson, and D. M. Grant.
1993.
Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Carcinogenesis
14:1633-1638[Abstract/Free Full Text].
|
| 28.
|
Hein, D. W.,
D. M. Grant, and E. Sim.
2000.
Update on consensus arylamine N-acetyltransferase gene nomenclature.
Pharmacogenetics
10:291-292[CrossRef][Medline].
|
| 29.
|
Hickman, D.,
J. Pope,
S. D. Patil,
G. Fakis,
V. Smelt,
L. A. Stanley,
M. Payton,
J. D. Unadkat, and E. Sim.
1998.
Expression of arylamine N-acetyltransferase in human intestine.
Gut
42:402-409[Abstract/Free Full Text].
|
| 30.
|
Ho, C.,
T. Lin,
Y. Lai,
J. Chung,
G. Levy, and W. Weber.
1996.
Kinetics of acetyl coenzyme A-arylamine N-acetyltransferase from rapid and slow acetylator frog tissues.
Drug Metab. Dispos.
24:137-141[Abstract].
|
| 31.
|
Horing, E.,
D. Gopfert,
G. Schroter, and U. von Gaisberg.
1991.
Frequency and spectrum of microorganisms isolated from biopsy specimens in chronic colitis.
Endoscopy
23:325-327[Medline].
|
| 32.
|
Hsieh, S. E.,
H. H. Lo,
Y. S. Chen, and J. G. Chung.
1997.
The effect of vitamin C on N-acetyltransferase activity in Klebsiella pneumoniae.
Food Chem. Toxicol.
35:1151-1157[CrossRef][Medline].
|
| 33.
|
Hsieh, S. E.,
H. H. Lo, and J. G. Chung.
1998.
The characteristics of arylamine N-acetyltransferase in Pseudomonas aeruginosa.
Curr. Microbiol.
36:353-360[CrossRef][Medline].
|
| 34.
|
Ilett, K. F.,
F. F. Kadlubar, and R. F. Minchin.
1999.
1998 international meeting on the arylamine N-acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk, Drug Metab.
Dispos.
27:957-959.
|
| 35.
|
Ireland, A.,
J. D. Priddle, and D. P. Jewell.
1990.
Comparison of 5-aminosalicylic acid and N-acetylaminosalicylic acid uptake by the isolated human colonic epithelial cell.
Gut
33:1343-1347[Abstract/Free Full Text].
|
| 36.
|
Ito, H.,
N. Kido,
Y. Arakawa,
M. Ohta,
T. Sugiyama, and N. Kato.
1991.
Possible mechanisms underlying the slow lactose fermentation phenotype in Shigella spp.
Appl. Environ. Microbiol.
57:2912-2917[Abstract/Free Full Text].
|
| 37.
|
Kelly, S. L., and E. Sim.
1994.
Arylamine N-acetyltransferase in BALB/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro.
Biochem. J.
302:347-353.
|
| 38.
|
Kitz, R., and I. B. Wilson.
1962.
Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase.
J. Biol. Chem.
237:3245-3249[Free Full Text].
|
| 39.
|
Lo, H. H., and J. G. Chung.
1999.
The effects of plant phenolics, caffeic acid, chlorogenic acid and ferulic acid on arylamine N-acetyltransferase activities in human gastrointestinal microflora.
Anticancer Res.
19:133-139[Medline].
|
| 40.
|
Maron, D. M., and B. N. Ames.
1983.
Revised methods for the Salmonella mutagenicity test.
Mutat. Res.
113:173-215[CrossRef][Medline].
|
| 41.
|
Marteau, P., and C. Cellier.
1997.
Effets indésirables de l'acide 5-aminosalicylique.
Gastroenterol. Clin. Biol.
21:377-386[Medline].
|
| 42.
|
Marteau, P., and M. Halphen.
1995.
Comparative randomized open study of the efficacy and tolerance of enemas with 2 gr of 4-aminosalicylic acid (4-ASA) and 1 gr of 5-aminosalicylic acid (5-ASA) in distal forms of hemorrhagic rectocolitis.
Gastroenterol. Clin. Biol.
19:31-35[Medline].
|
| 43.
|
McCoy, E. C.,
H. S. Rosenkranz, and R. Mermelstein.
1981.
Evidence for the existence of a family of bacterial nitroreductases capable of activating nitrated polycyclics to mutagens.
Environ. Mutagen.
3:421-427[Medline].
|
| 44.
|
Nakayama, H.,
T. Kinouchi,
K. Kataoka,
S. Akimoto,
Y. Matsuda, and Y. Ohnishi.
1997.
Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.
Pharmacogenetics
7:35-43[CrossRef][Medline].
|
| 45.
|
Neidhardt, F. C.
1987.
Chemical composition of Escherichia coli, p. 3-6.
In
F. C. Neidhardt, et al. (ed.), Escherichia coli and Salmonella typhimurium: cellular and molecular biology. American Society for Microbiology, Washington, D.C.
|
| 46.
|
Neut, C.,
J. F. Colombel,
F. Guillemot,
A. Cortot,
P. Gower,
P. Quandalle,
M. Ribet,
C. Romond, and J. C. Paris.
1989.
Impaired bacterial flora in human excluded colon.
Gut
30:1094-1098[Abstract/Free Full Text].
|
| 47.
|
Ohsako, S.,
M. Ohtomi,
Y. Sakamoto,
K. Uyemura, and T. Deguchi.
1988.
Arylamine N-acetyltransferase from chicken liver: cloning of cDNA and expression in Chinese hamster ovary cells.
J. Biol. Chem.
263:7534-7538[Abstract/Free Full Text].
|
| 48.
|
Okumura, F.,
O. Ueda,
S. Kitamura, and K. Tatsumi.
1995.
N-Acetylation and N-formylation of carcinogenic arylamines and related compounds in dogs.
Carcinogenesis
16:71-76[Abstract/Free Full Text].
|
| 49.
|
Payton, M.,
R. Auty,
R. Delgoda,
M. Everett, and E. Sim.
1999.
Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance.
J. Bacteriol.
181:1343-1347[Abstract/Free Full Text].
|
| 50.
|
Prantera, C., and M. L. Scribano.
1999.
Current treatment for prevention of relapse and recurrence in Crohn's disease.
Ital. J. Gastroenterol. Hepatol.
31:515-518[Medline].
|
| 51.
|
Reddy, B. S.,
J. R. Pleasants, and B. S. Wostmann.
1969.
Pancreatic enzymes in germfree and conventional rats fed chemically defined, water-soluble diet free from natural substrates.
J. Nutr.
97:327-334.
|
| 52.
|
Sandberg-Gertzen, H.,
J. Kjellander,
B. Sundberg-Gilla, and G. Jarnerot.
1985.
In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria.
Scand. J. Gastroenterol.
20:607-612[Medline].
|
| 53.
|
Sasaki, Y.,
S. Ohsako, and T. Deguchi.
1991.
Molecular and genetic analyses of arylamine N-acetyltransferase polymorphism of rabbit liver.
J. Biol. Chem.
266:13243-13250[Abstract/Free Full Text].
|
| 54.
|
Sim, E.,
M. Payton,
M. Noble, and R. Minchin.
2000.
An update on genetic structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes.
Hum. Mol. Genet.
9:2435-2441[Abstract/Free Full Text].
|
| 55.
|
Simmonds, N. J.,
A. D. Millar,
D. R. Blake, and D. S. Rampton.
1999.
Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.
Aliment. Pharmacol. Ther.
13:363-372[CrossRef][Medline].
|
| 56.
|
Simons, G. L., and S. L. Gorbach.
1981.
Intestinal flora in health and disease, p. 1361-1380.
In
L. R. Johnson (ed.), Physiology of the gastrointestinal tract. Raven Press, New York, N.Y.
|
| 57.
|
Sinclair, J. C.,
R. Delgoda,
M. E. M. Noble,
S. Jarmia,
N. K. Goh, and E. Sim.
1998.
Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium.
Protein Expr. Purif.
12:371-380[CrossRef][Medline].
|
| 58.
|
Sinclair, J. C.,
J. Sandy,
R. Delgoda,
E. Sim, and M. E. M. Noble.
2000.
Structure of arylamine N-acetyltransferase reveals a catalytic triad.
Nat. Struct. Biol.
7:560-564[CrossRef][Medline].
|
| 59.
|
Thomson, A. B. R., and C. N. Williams.
1999.
Trends in inflammatory bowel disease therapy.
Can. J. Gastroenterol.
13:775-776[Medline].
|
| 60.
|
Tomb, J. F.,
O. White,
A. R. Kerlavage,
R. A. Clayten,
G. G. Sutton,
R. D. Fleischmann,
K. A. Ketchum,
H. P. Klenk,
S. Gill,
B. A. Dougherty,
K. Nelson,
J. Quackenbush,
L. Zhou,
E. F. Kirkness,
S. Peterson,
B. Loftus,
D. Richardson,
R. Dodson,
H. G. Khalak,
A. Glodek,
K. McKenney,
L. M. Fitzegerald,
N. Lee,
M. D. Adams,
J. C. Venter, et al.
1997.
The complete genome sequence of the gastric pathogen Helicobacter pylori.
Nature
388:539-547[CrossRef][Medline]. (Erratum, 389:412.)
|
| 61.
|
Tsou, M. F.,
J. G. Chung,
L. T. Wu,
K. S. Cheng, and C. F. Hung.
1998.
Characterization of arylamine N-acetyltransferase in Enterobacter aerogenes.
Microbios
94:133-143[Medline].
|
| 62.
|
Tsou, M. F.,
C. F. Hung,
H. F. Lu,
L. T. Wu,
S. H. Chang,
H. L. Chang,
G. W. Chen, and J. G. Chung.
2000.
Effects of caffeic acid, chlorogenic acid and ferulic acid on growth and arylamine N-acetyltransferase activity in Shigella sonnei (group D).
Microbios
101:37-46[Medline].
|
| 63.
|
van Hogezand, R. A.,
H. M. Kennis,
A. van Schaik,
J. P. Koopman,
P. A. van Hees, and J. H. Tongeren.
1992.
Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.
Eur. J. Clin. Pharmacol.
43:189-192[CrossRef][Medline].
|
| 64.
|
Watanabe, M.,
M. J. Ishidate, and T. Nohmi.
1990.
Sensitive method for the detection of mutagenic nitroarenes and aromatic amines: new derivatives of Salmonella typhimurium tester strains possessing elevated O-acetyltransferase levels.
Mutat. Res.
234:337-348[CrossRef][Medline].
|
| 65.
|
Watanabe, M.,
T. Sofuni, and T. Nohmi.
1992.
Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium: sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms.
J. Biol. Chem.
267:8429-8436[Abstract/Free Full Text].
|
| 66.
|
Whitaker, D. P., and M. W. Goosey.
1993.
Purification and properties of the enzyme arylamine N-acetyltransferase from the housefly Musca domestica.
Biochem. J.
295:149-154.
|
| 67.
|
Zeitz, M.
1999.
Consequences of galenic considerations and clinical results for therapy of ulcerative colitis.
Med. Klin.
94(Suppl. 1):41-43. (In German.)
|
| 68.
|
Zhou, S. Y.,
D. Fleisher,
L. H. Pao,
C. Li,
B. Winward, and E. M. Zimmermann.
1999.
Intestinal metabolism and transport of 5-aminosalicylate.
Drug Metab. Dispos.
27:479-485[Abstract/Free Full Text].
|
Journal of Bacteriology, June 2001, p. 3417-3427, Vol. 183, No. 11
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.11.3417-3427.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Suzuki, H., Ohnishi, Y., Horinouchi, S.
(2007). Arylamine N-Acetyltransferase Responsible for Acetylation of 2-Aminophenols in Streptomyces griseus. J. Bacteriol.
189: 2155-2159
[Abstract]
[Full Text]
-
Atmane, N., Dairou, J., Paul, A., Dupret, J.-M., Rodrigues-Lima, F.
(2003). Redox Regulation of the Human Xenobiotic Metabolizing Enzyme Arylamine N-Acetyltransferase 1 (NAT1): REVERSIBLE INACTIVATION BY HYDROGEN PEROXIDE. J. Biol. Chem.
278: 35086-35092
[Abstract]
[Full Text]
-
Mushtaq, A., Payton, M., Sim, E.
(2002). The COOH Terminus of Arylamine N-Acetyltransferase from Salmonella typhimurium Controls Enzymic Activity. J. Biol. Chem.
277: 12175-12181
[Abstract]
[Full Text]
-
Payton, M., Gifford, C., Schartau, P., Hagemeier, C., Mushtaq, A., Lucas, S., Pinter, K., Sim, E.
(2001). Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis. Microbiology
147: 3295-3302
[Abstract]
[Full Text]